Journal article
PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia
Abstract
Allosteric modulators are emerging as new therapeutics for the treatment of psychiatric illnesses, such as schizophrenia. Conventional antipsychotic drugs are typically dopamine D2 receptor antagonists that compete with endogenous dopamine at the orthosteric site, and block excessive dopamine neurotransmission in the brain. However, they are unable to treat all symptoms of schizophrenia and often cause adverse motor and metabolic side effects. …
Authors
Beyaert MGR; Daya RP; Dyck BA; Johnson RL; Mishra RK
Journal
European Neuropsychopharmacology, Vol. 23, No. 3, pp. 253–262
Publisher
Elsevier
Publication Date
March 2013
DOI
10.1016/j.euroneuro.2012.04.010
ISSN
0924-977X